Introduction: Graves’ disease associated with comorbidities can increase morbidity and mortality. Our objective was to describe the epidemiological, clinical, therapeutic and evolutionary aspects of comorbidities ass...Introduction: Graves’ disease associated with comorbidities can increase morbidity and mortality. Our objective was to describe the epidemiological, clinical, therapeutic and evolutionary aspects of comorbidities associated with Graves’ disease at the Abass hospital center, Ndao. Methods: This was a cross-sectional and descriptive study conducted from January 2020 to December 2020. It focused on patients followed for Graves’ disease at Abass hospital, Ndao de Dakar. Epidemiological, clinical, therapeutic and evolutionary data were evaluated. Results: Three hundred and three eighteen (318) cases were collected, 70 of which had comorbidities (51.15%). The average age was 38.45 years with extremes ranging from 15 to 71 years. Women represented 91.42% of patients. A consultation delay of more than one year was noted in 24.29%. Cardiovascular comorbidities were dominated by hypertension with 30%. Graves’ disease was associated with an evolving pregnancy in 10 women. Endocrine comorbidities were dominated by type 1 diabetes noted in 8.57% each. Biermer’s disease was noted in 2 patients. Female gender was the most common etiological factor of Graves’ disease noted in 64 patients (91.42%). A hereditary predisposition existed in 4 patients (5.71%), stress was noted in 7 patients (10%). 43 patients were under thyrozol (61.42%), 41 patients were on propranolol (58.57%), 14 patients were on carbimazole (20%). A good balance was noted in 44 cases (68.75%) after 9 months of treatment. Conclusion: Graves’ disease is a public health problem with nonspecific signs. It requires screening and treating comorbidities to reduce morbidity and mortality.展开更多
<div style="text-align:justify;"> <span style="font-family:Verdana;"><strong>Background:</strong> The <sup>99m</sup>TcO<sub>4</sub><sup style=&quo...<div style="text-align:justify;"> <span style="font-family:Verdana;"><strong>Background:</strong> The <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy is commonly used for hyperthyroidism diagnosis. Uptake value of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> on thyroid scintigraphy is an indicator of hyperthyroidism activity. Although, the correlation between free T3 value and free T4 value is not necessary clear in primary hyperthyroidism. <strong>Introduction: </strong>This study investigated the correlation between results of blood test and uptake of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> on thyroid scintigraphy in primary hyperthyroidism. <strong>Methodlogy: </strong>In this retrspective study, uptake was calculated in patients diagnosed with primary hyperthyroidism (Graves’ disease/Basedow’s disease) based on clinical findings, blood tests, thyroid ultrasound, and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy (uptake ≥3%) at St. Marianna University School of Medicine Hospital between 1 January 2010 and 31 December 2019. This uptake of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> was compared with results of blood tests. <strong>Results:</strong> Fifty-four consecutively arriving patients at the hospital (12 men, 42 women;mean age 43.0 ± 14.0 years) were selected. Free T3 (n = 54) was 14.6 ± 6.8 pg/mL, free T4 (n = 53) was 5.0 ± 2.3 ng/mL, and uptake on thyroid scintigraphy was 10.0% ± 7.1%. The correlation coefficients were 0.60 (p < 0.01) between free T4 (all case), 0.39 (p < 0.01) between free T4 (under 7 ng/mL), 0.12 (p = 0.70) between free T4 (above 7 ng/mL) and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy uptake. <strong>Conclusion:</strong> In primary hyperthyroidism (Graves’ disease), there is a correlation between free T4 value and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy uptake, but there is no correlation in patients with high free T4 level.</span> </div>展开更多
文摘Introduction: Graves’ disease associated with comorbidities can increase morbidity and mortality. Our objective was to describe the epidemiological, clinical, therapeutic and evolutionary aspects of comorbidities associated with Graves’ disease at the Abass hospital center, Ndao. Methods: This was a cross-sectional and descriptive study conducted from January 2020 to December 2020. It focused on patients followed for Graves’ disease at Abass hospital, Ndao de Dakar. Epidemiological, clinical, therapeutic and evolutionary data were evaluated. Results: Three hundred and three eighteen (318) cases were collected, 70 of which had comorbidities (51.15%). The average age was 38.45 years with extremes ranging from 15 to 71 years. Women represented 91.42% of patients. A consultation delay of more than one year was noted in 24.29%. Cardiovascular comorbidities were dominated by hypertension with 30%. Graves’ disease was associated with an evolving pregnancy in 10 women. Endocrine comorbidities were dominated by type 1 diabetes noted in 8.57% each. Biermer’s disease was noted in 2 patients. Female gender was the most common etiological factor of Graves’ disease noted in 64 patients (91.42%). A hereditary predisposition existed in 4 patients (5.71%), stress was noted in 7 patients (10%). 43 patients were under thyrozol (61.42%), 41 patients were on propranolol (58.57%), 14 patients were on carbimazole (20%). A good balance was noted in 44 cases (68.75%) after 9 months of treatment. Conclusion: Graves’ disease is a public health problem with nonspecific signs. It requires screening and treating comorbidities to reduce morbidity and mortality.
文摘<div style="text-align:justify;"> <span style="font-family:Verdana;"><strong>Background:</strong> The <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy is commonly used for hyperthyroidism diagnosis. Uptake value of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> on thyroid scintigraphy is an indicator of hyperthyroidism activity. Although, the correlation between free T3 value and free T4 value is not necessary clear in primary hyperthyroidism. <strong>Introduction: </strong>This study investigated the correlation between results of blood test and uptake of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> on thyroid scintigraphy in primary hyperthyroidism. <strong>Methodlogy: </strong>In this retrspective study, uptake was calculated in patients diagnosed with primary hyperthyroidism (Graves’ disease/Basedow’s disease) based on clinical findings, blood tests, thyroid ultrasound, and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy (uptake ≥3%) at St. Marianna University School of Medicine Hospital between 1 January 2010 and 31 December 2019. This uptake of <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> was compared with results of blood tests. <strong>Results:</strong> Fifty-four consecutively arriving patients at the hospital (12 men, 42 women;mean age 43.0 ± 14.0 years) were selected. Free T3 (n = 54) was 14.6 ± 6.8 pg/mL, free T4 (n = 53) was 5.0 ± 2.3 ng/mL, and uptake on thyroid scintigraphy was 10.0% ± 7.1%. The correlation coefficients were 0.60 (p < 0.01) between free T4 (all case), 0.39 (p < 0.01) between free T4 (under 7 ng/mL), 0.12 (p = 0.70) between free T4 (above 7 ng/mL) and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy uptake. <strong>Conclusion:</strong> In primary hyperthyroidism (Graves’ disease), there is a correlation between free T4 value and <sup>99m</sup>TcO<sub>4</sub><sup style="margin-left:-7px;">-</sup> thyroid scintigraphy uptake, but there is no correlation in patients with high free T4 level.</span> </div>